Hims & Hers Expands Offerings and Global Reach with Strategic Acquisitions and New Services

Hims & Hers Health, Inc., a leading telehealth platform, is making significant strides in expanding its services and global footprint through a series of strategic moves announced this week. The company is evolving its direct-to-consumer model by venturing into diagnostics, entering new international markets, and broadening its product portfolio.

Acquisition of YourBio Health Marks Entry into Advanced Diagnostics

In a move to revolutionize blood sampling technology, Hims & Hers has agreed to acquire YourBio Health, Inc., a Boston-based company specializing in capillary whole blood sampling. The acquisition, set to close in early 2026, will integrate YourBio Health's innovative "Touch-Activated Phlebotomy" (TAP) device into Hims & Hers' offerings.

The TAP device utilizes bladeless microneedles thinner than an eyelash to collect high-quality capillary blood samples within seconds, promising a pain-free alternative to traditional blood collection methods. This technology aligns with Hims & Hers' goal of simplifying and modernizing the blood collection experience.

Andrew Dudum, founder and CEO of Hims & Hers, emphasized the importance of this acquisition, stating, "The next generation of health innovation will be built on proprietary technologies that make wellness simpler, more comfortable, and more human." The deal, funded entirely from Hims & Hers' balance sheet, is expected to accelerate the company's efforts in redefining blood collection standards.

Expansion into Canada and Enhanced Diagnostic Services

Hims & Hers is extending its reach beyond U.S. borders with its entry into the Canadian market. This move coincides with the anticipated availability of generic semaglutide in Canada, allowing the company to launch its weight loss program in the country. The expansion follows Hims & Hers' recent acquisition of Livewell, a Canadian digital health platform specializing in weight loss treatments.

In addition to geographical expansion, Hims & Hers is broadening its diagnostic capabilities. The company recently launched a new Labs offering in partnership with Quest Diagnostics, enabling customers to undergo comprehensive blood tests at local facilities. These tests can analyze up to 120 biomarkers across various health categories, including heart health, metabolism, and hormones. The service aims to provide personalized treatment plans based on individual test results.

The Labs offering is available in two tiers: a base plan priced at $199 annually for 50 biomarker tests, and an advanced plan at $499 annually for over 120 biomarker tests. CEO Andrew Dudum has expressed high expectations for this new venture, projecting it to potentially become a $1 billion business.